Your browser doesn't support javascript.
loading
Cefiderocol: Clinical application and emergence of resistance.
Wang, Liang; Zhu, Jie; Chen, Liang; Du, Hong.
Afiliação
  • Wang L; Department of Clinical Laboratory, The Second Affiliated Hospital of Soochow University, Suzhou, China; MOE Key Laboratory of Geriatric Diseases and Immunology, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215123 China.
  • Zhu J; Department of Clinical Laboratory, The Second Affiliated Hospital of Soochow University, Suzhou, China.
  • Chen L; Hackensack Meridian Health Center for Discovery and Innovation, Nutley, NJ, United States; Department of Medical Sciences, Hackensack Meridian School of Medicine, Nutley, NJ, United States.
  • Du H; Department of Clinical Laboratory, The Second Affiliated Hospital of Soochow University, Suzhou, China; MOE Key Laboratory of Geriatric Diseases and Immunology, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215123 China. Electronic address: hong_du@126.com.
Drug Resist Updat ; 72: 101034, 2024 Jan.
Article em En | MEDLINE | ID: mdl-38134561
ABSTRACT
Antibacterial drug resistance of gram-negative bacteria (GNB) results in high morbidity and mortality of GNB infection, seriously threaten human health globally. Developing new antibiotics has become the critical need for dealing with drug-resistant bacterial infections. Cefiderocol is an iron carrier cephalosporin that achieves drug accumulation through a unique "Trojan horse" strategy into the bacterial periplasm. It shows high antibacterial activity against multidrug-resistant (MDR) Enterobacteriaceae and MDR non-fermentative bacteria. The application of cefiderocol offers new hope for treating clinical drug-resistant bacterial infections. However, limited clinical data and uncertainties about its resistance mechanisms constrain the choice of its therapeutic use. This review aimed to summarize the clinical applications, drug resistance mechanisms, and co-administration of cefiderocol.
Assuntos
Palavras-chave

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Infecções por Bactérias Gram-Negativas / Cefiderocol Limite: Humans Idioma: En Revista: Drug Resist Updat Assunto da revista: ANTINEOPLASICOS Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Infecções por Bactérias Gram-Negativas / Cefiderocol Limite: Humans Idioma: En Revista: Drug Resist Updat Assunto da revista: ANTINEOPLASICOS Ano de publicação: 2024 Tipo de documento: Article